Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 6/20 | 0.62 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13168592 | 0.88 | SCN4A (0.56) | SCN4ASCN9AHSPB1MAPTSMN1; SMN2 | |
| SCHEMBL13168517 | 0.87 | SCN4A (0.74) | SCN4ASCN9AHSPB1MAPTALDH1A1 | |
| SCHEMBL13168623 | 0.80 | SCN4A (0.62) | SCN4ASCN9AMGLL | |
| SCHEMBL1384380 | 0.77 | SCN4A (1.00) | SCN4ASCN9AMGLL | |
| SCHEMBL1384489 | 0.74 | SCN4A (0.77) | SCN4AHSPB1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL27859313 | 0.73 | HSPB1 (0.82) | HSPB1MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL6702108 | 0.73 | SCN4A (0.57) | SCN4AMAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3365086 | 0.72 | SCN4A (1.00) | SCN4ASCN9AHSPB1MAPTSMN1; SMN2 | |
| SCHEMBL22529905 | 0.71 | HSPB1 (0.62) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL13168622 | 0.71 | SCN4A (1.00) | SCN4ASCN9AHSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100247435-A1 | MEASUREMENT OF NEURAL ACTIVITY | ARSTAD ERIK | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247435-A1 | MEASUREMENT OF NEURAL ACTIVITY | GAP43, ACHE, BDNF | SCN4A 399/4885SCN9A 824/4885HSPB1 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.